The benchmark 10-year Treasury note reversed early declines to rise for the fourth straight day, while big technology and growth names like Apple Inc, Amazon.com and Nvidia Corp cut back gains
The company said it expects some impact of inflation to ease next year but higher costs of inventory manufactured in 2022 could weigh on 2023 profit
Maharashtra's Food and Drugs Administration (FDA) on Friday cancelled the baby powder manufacturing licence of Johnson & Johnson Pvt Ltd "in the interest of public health at large". In a release, the state government agency said the company's product, Johnson's Baby Powder, may affect the skin of newborn babies. Samples of the powder for babies did not conform to standard pH value during a laboratory test, the regulator said. The release said the action was taken after Kolkata-based Central Drugs Laboratory's conclusive report that concludes "the sample does not conform to IS 5339:2004 with respect to the test for pH. According to the release, FDA had drawn samples of Johnson's Baby Powder from Pune and Nashik for quality check purposes. The government analyst had declared the samples as "not of the standard quality" as they do not comply with IS 5339:2004 specification for skin powder for infants in the test pH, it said. Thereafter, FDA issued a show-cause notice to ...
Johnson and Johnson (J&J) has been facing several thousand lawsuits from women who claim that they developed ovarian cancer after using the product
After 38,000 serious allegations, Johnson and Johnson's talc-based baby powder will stop international sales from 2023. The product has already been discontinued in the US and Canada
(Reuters) -Johnson & Johnson on Thursday put into bankruptcy tens of thousands of legal claims alleging its Baby Powder and other talc-based products caused cancer, offloading the potential liabilities into a newly created subsidiary.
SEC asks J&J to monitor adverse events closely for next three months
Now India has 5 EUA vaccines. This will further boost our nation's collective fight against Covid, says Union Health Minister Mansukh Mandaviya
A team of central government officials is in continuous dialogue with foreign Covid vaccine manufactures like Pfizer, Moderna and Johnson and Johnson to discuss and address various issues
FDA adds warning on Johnson & Johnson vaccine, lockdown extensions looms in Sydney and other pandemic-related news across the globe
New Delhi [India], July 2 (ANI): NITI Aayog member (Health) Dr VK Paul on Friday confirmed that India is in talks with US pharma giant Johnson & Johnson for their single-dose COVID-19 vaccine named Janssen.Speaking exclusively to ANI, Dr Paul said, "We are in talks with Johnson & Johnson regarding their single-dose vaccine."He said that "as per the plan, this vaccine will also be produced in Hyderabad's Bio E."Johnson & Johnson said late on Thursday that its COVID-19 vaccine showed strong promise against the Delta variant and other emerging strains and also provided durable protection against the infection more broadly. The healthcare company in a statement said that its vaccine was 85 per cent effective and could also help prevent hospitalisation and death.Presently, in India Delta plus has been reported in 12 states. This variant is a sub-lineage of delta variant and has been declared as 'Variant of Concern' by the government.According to Dr Paul, India reported 56
Johnson & Johnson said Thursday that U.S. regulators extended the expiration date on millions of doses of its COVID-19 vaccine by six weeks. The company said a Food and Drug Administration review concluded the shots remain safe and effective for at least 4 1/2 months. In February, the FDA originally authorised J&J's vaccine for up to three months when stored at normal refrigeration levels. Thursday's announcement comes after state officials warned that many doses in storage would expire before the end of the month. Vaccine expiration dates are based on information from drugmakers on how long the shots stay at the right strength. J&J said the FDA added six weeks based on data from ongoing studies assessing the vaccine's stability. The FDA has been reviewing expiration dates on all three U.S. authorised vaccines as companies have continued to test batches in the months since the shots first rolled out. The vaccines from Pfizer and Moderna, authorized in December, have a ...
Belgium on Wednesday suspended the use of the Johnson & Johnson COVID-19 vaccine for people under age 41 following the death of a person who had received the shot. The government said in a statement it was asking for urgent advice from the European Medicines Agency, the European Union's drug regulator, before it would consider lifting the suspension. It added that the impact on the national vaccination drive would be very limited. Belgium was using the Johnson & Johnson vaccine for elderly with reduced mobility and the homeless since it only takes one shot to be protected. Those shots will be continued. It said it took the action after a single case where there was serious side effects after administering the Janssen vaccine, using the local name for the Johnson & Johnson shot. It said a woman was vaccinated through her foreign employer outside the Belgian system and had died in Belgium last week after developing serious thrombosis and reduced blood platelets. It didn't ...
US pharmaceutical giant Johnson and Johnson has joined hands with Biological E Limited (Telangana-based pharma company) for the manufacturing of the COVID-19 vaccine, as per an official statement on Tuesday.The company's vaccine named, Janssen COVID-19 vaccine is currently approved for use in the United States, the European Union and other nations including Thailand and South Africa."Johnson & Johnson is working with Biological E. Limited on the manufacturing of the Johnson COVID-19 vaccine. We believe Biological E. will be an important part of our global COVID-19 vaccine supply network, where multiple manufacturing sites are involved in the production of our vaccine across different facilities, sometimes in different countries and continents, before the vaccine can be distributed", read an official statement by Johnson and Johnson."We are working around the clock to develop and broadly activate our manufacturing capabilities to supply our COVID-19 vaccine worldwide and we ...
US is looking at joint production of Johnson and Johnson's Covid-19 vaccine in India and ways to help manufacturers like the Serum Institute of India to boost production
The European Union's drug regulatory agency said Tuesday that it found a possible link between Johnson & Johnson's COVID-19 vaccine and extremely rare blood clots and that a warning should be added to the label. But experts at the agency reiterated that the vaccine's benefits outweigh the risks. The European Medicines Agency made those determinations after a very small number of blood clot cases in people who had gotten the vaccine were reported in the United States. The agency said a warning about the blood clots should be added to labels for the Johnson & Johnson's vaccine and that these rare blood disorders should be considered very rare side effects of the vaccine. The EMA also recommended a label change for the AstraZeneca COVID-19 vaccine after finding a link between it and rare blood clots. In both cases, the agency said the benefits of being immunized against COVID-19 still outweighed the very small risks of recipients developing the unusual clots. Last week, Johnson ..
A spokesman for the EU Commission said it was keeping all options open to be prepared for the next stages of the pandemic, for 2022 and beyond
South African Health Minister Zweli Mkhize on Tuesday said that the country will be suspending the use of the Johnson & Johnson COVID-19 vaccine after health concerns raised by the US Food and Drug Administration (FDA)."We have determined to voluntarily suspend our rollout until the causal relationship between the development of clots and the Johnson and Johnson vaccine is sufficiently interrogated," Mkhize said in a statement."In the extremely unlikely event that Johnson and Johnson rollout is completely halted, we will not have any impediment to proceed with phase two of the rollout with Pfizer," he added.This comes after the US Centers of Disease Control and Prevention (CDC) and the FDA recommended a "pause" in the use of the Johnson and Johnson COVID-19 vaccine "out of an abundance of caution" over six reported cases in the US of a "rare and severe" type of blood clot.In a joint statement, the CDC and the FDA said they were investigating clots in six women in the days after .
The USFDA said one person had died from the rare blood clotting condition after taking the J&J vaccine and another was in a critical condition
Business Standard brings you top news of the evening